Have Insiders Sold ANI Pharmaceuticals Shares Recently?

Anyone interested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) should probably be aware that the Senior Vp & Head of Rare Disease, Christopher Mutz, recently divested US$242k worth of shares in the company, at an average price of US$60.45 each. On the bright side, that sale was only 3.6% of their holding, so we doubt it's very meaningful, on its own.

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

The Last 12 Months Of Insider Transactions At ANI Pharmaceuticals

Over the last year, we can see that the biggest insider sale was by the Senior VP of Finance & CFO, Stephen Carey, for US$418k worth of shares, at about US$55.79 per share. That means that an insider was selling shares at slightly below the current price (US$59.08). We generally consider it a negative if insiders have been selling, especially if they did so below the current price, because it implies that they considered a lower price to be reasonable. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 4.6% of Stephen Carey's holding.

ANI Pharmaceuticals insiders didn't buy any shares over the last year. The chart below shows insider transactions (by companies and individuals) over the last year. By clicking on the graph below, you can see the precise details of each insider transaction!

Check out our latest analysis for ANI Pharmaceuticals

I will like ANI Pharmaceuticals better if I see some big insider buys. While we wait, check out this free list of undervalued and small cap stocks with considerable, recent, insider buying.

Does ANI Pharmaceuticals Boast High Insider Ownership?

Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. A high insider ownership often makes company leadership more mindful of shareholder interests. ANI Pharmaceuticals insiders own 8.9% of the company, currently worth about US$108m based on the recent share price. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.

So What Do The ANI Pharmaceuticals Insider Transactions Indicate?

Insiders sold ANI Pharmaceuticals shares recently, but they didn't buy any. Looking to the last twelve months, our data doesn't show any insider buying. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing ANI Pharmaceuticals. At Simply Wall St, we found 1 warning sign for ANI Pharmaceuticals that deserve your attention before buying any shares.

Of course ANI Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.